All Photos(1)

Documents

Y0000762

Fluorouracil impurity A

Name: Fluorouracil impurity A
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Barbituric acid, 2,4,6-Trihydroxypyrimidine, Malonylurea

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₄H₄N₂O₃

CAS Number:

67-52-7

Molecular Weight:

128.09

Beilstein/REAXYS Number:

120502

MDL number:

MFCD00006666

UNSPSC Code:

12352200

PubChem Substance ID:

329831134

NACRES:

NA.24

Recommended Products

Slide 1 of 10

1 of 10

Sigma-Aldrich

185698

Barbituric acid

USP

1029512

Amlodipine Related Compound A

USP

1029545

Amlodipine Related Compound D

Supelco

1.00132

Barbituric acid

Sigma-Aldrich

11715

Sodium barbiturate

Y0001067

Amlodipine for peak identification

Y0001068

Amlodipine impurity A

USP

1279019

Fluorouracil Related Compound A

USP

1279021

Fluorouracil Related Compound B

Supelco

I0627

Isobarbituric acid

grade

pharmaceutical primary standard

API family

fluorouracil

manufacturer/tradename

EDQM

mp

248-252 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1CC(=O)NC(=O)N1

InChI

1S/C4H4N2O3/c7-2-1-3(8)6-4(9)5-2/h1H2,(H2,5,6,7,8,9)

InChI key

HNYOPLTXPVRDBG-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluorouracil impurity A EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1279054

1279065

1279019

1279021

BP995

Fluorouracil, British Pharmacopoeia (BP) Reference Standard

PHR2584

5,6-Diamino-1,3-dimethyluracil, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2865

PHR2866

PHR2867

PHR2868

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

302.0 °F - closed cup

flash_point_c

150.00 °C - closed cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Identifying barbiturate binding sites in a nicotinic acetylcholine receptor with [3H]allyl m-trifluoromethyldiazirine mephobarbital, a photoreactive barbiturate.

Ayman K Hamouda et al.

Molecular pharmacology, 85(5), 735-746 (2014-02-25)

At concentrations that produce anesthesia, many barbituric acid derivatives act as positive allosteric modulators of inhibitory GABAA receptors (GABAARs) and inhibitors of excitatory nicotinic acetylcholine receptors (nAChRs). Recent research on [(3)H]R-mTFD-MPAB ([(3)H]R-5-allyl-1-methyl-5-(m-trifluoromethyldiazirinylphenyl)barbituric acid), a photoreactive barbiturate that is a potent

Is there new hope for therapeutic matrix metalloproteinase inhibition?

Roosmarijn E Vandenbroucke et al.

Nature reviews. Drug discovery, 13(12), 904-927 (2014-11-08)

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that form a family of 24 members in mammals. Evidence of the pathological roles of MMPs in various diseases, combined with their druggability, has made them attractive therapeutic targets. Initial drug discovery efforts focused

Hydrolytic pathway of 5-fluorouracil in aqueous solutions for clinical use.

Rémi Legay et al.

Journal of pharmaceutical and biomedical analysis, 98, 446-462 (2014-07-20)

The purpose of the study was to investigate the degradation pathway of 5-fluorouracil (FU) in the situation of commercial formulations for clinical use, namely FU dissolved in sodium hydroxide (NaOH) solutions or Tris buffer at pH 8.5-9. Combination of data

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service